Healthlead Future Growth
Future criteria checks 2/6
Healthlead is forecast to grow earnings and revenue by 14.2% and 12.4% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 10.1% in 3 years.
Key information
14.2%
Earnings growth rate
13.7%
EPS growth rate
Consumer Retailing earnings growth | 17.2% |
Revenue growth rate | 12.4% |
Future return on equity | 10.1% |
Analyst coverage | Low |
Last updated | 15 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,371 | 113 | 105 | N/A | 1 |
12/31/2025 | 2,195 | 101 | 72 | N/A | 1 |
12/31/2024 | 1,835 | 84 | 133 | N/A | 1 |
12/31/2023 | 1,659 | 75 | 8 | 91 | N/A |
9/30/2023 | 1,604 | 79 | -7 | 68 | N/A |
6/30/2023 | 1,590 | 94 | 0 | 83 | N/A |
3/31/2023 | 1,552 | 101 | 13 | 96 | N/A |
12/31/2022 | 1,538 | 118 | 16 | 136 | N/A |
9/30/2022 | 1,447 | 106 | 39 | 140 | N/A |
6/30/2022 | 1,400 | 100 | 46 | 130 | N/A |
3/31/2022 | 1,332 | 95 | 72 | 142 | N/A |
12/31/2021 | 1,216 | 80 | 70 | 85 | N/A |
9/30/2021 | 1,196 | 71 | 94 | 109 | N/A |
3/31/2021 | 1,030 | 44 | 32 | 46 | N/A |
1/1/2021 | 1,080 | 52 | 82 | 97 | N/A |
12/31/2019 | 935 | 22 | N/A | N/A | N/A |
12/31/2018 | 791 | 0 | 20 | 33 | N/A |
12/31/2017 | 701 | -9 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HL-R's forecast earnings growth (14.2% per year) is above the savings rate (1.9%).
Earnings vs Market: HL-R's earnings (14.2% per year) are forecast to grow slower than the TH market (15.2% per year).
High Growth Earnings: HL-R's earnings are forecast to grow, but not significantly.
Revenue vs Market: HL-R's revenue (12.4% per year) is forecast to grow faster than the TH market (7% per year).
High Growth Revenue: HL-R's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HL-R's Return on Equity is forecast to be low in 3 years time (10.1%).